FIELD: medicine.
SUBSTANCE: the present innovation deals with treating certain neurological and psychic disorders in mammalians including human beings and refers to the introduction of a selective inhibitor PDE10, moreover, the innovation in question deals with the ways to identify chemical compound that possesses he efficiency of a selective inhibitor PDE10. The innovation enables to develop new method for screening the compounds for the presence of the ability to selectively inhibit PDE10.
EFFECT: higher efficiency.
2 cl, 6 dwg, 7 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SUCCINATE 2-((4-(1-METHYL-4-(PYRIDIN-4-YL)-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE SALT | 2007 |
|
RU2430918C2 |
| ORGANIC COMPOUNDS | 2014 |
|
RU2679142C2 |
| HYDININE DERIVATIVES AS INHERITORS OF FERMENT PDE10A | 2012 |
|
RU2624440C2 |
| POLYPEPTIDE WITH PHOSPHODIESTERASE ENZYMATIC ACTIVITY | 1998 |
|
RU2272841C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2709786C2 |
| COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO[4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | 2013 |
|
RU2657540C2 |
| COMPOUNDS AND METHODS | 2015 |
|
RU2711442C2 |
| NOVEL PEPTIDE-INHIBITOR PI3Kγ FOR TREATING RESPIRATORY DISEASES | 2015 |
|
RU2704826C2 |
| PHARMACEUTICAL COMPOSITION FOR CYCLIC ADENOSIN-PHONESPHATE CONTENT AND AVAILABILITY INCREASE IN ORGANISM AND ITS PRODUCTION | 2012 |
|
RU2625765C2 |
| TRANSGENIC ANIMAL THAT DIFFERS FROM HUMAN, AND ITS APPLICATION | 2010 |
|
RU2579701C2 |
